title: [The investment of pharmaceutical industry in hospital clinical research: an             estimate for france in 2010].
abstract: The objective of this study was to estimate the investment of pharmaceutical industry in hospital clinical research in France for 2010. The method consisted in combining data extracted from various sources about volumes of patients and unit costs per patient according to phase (I, II and II) and therapeutic domains. The numbers of French patients enrolled were estimated through an extraction of the National Institute of Health (NIH) database. Unit costs per patient were estimated from a sample of 54 clinical studies covering the most frequent combinations of phases and therapeutic domains and documented independently by 5 international companies. We identified 1, 178 clinical studies ongoing in 2010, having included a total of about 73, 000 French patients. Among these studies, 40.3% and 12.8% concerned Onco-Haematology and Rare Diseases respectively. The total annual investment from industry was estimated at 488 million euros, comprising 83.6 M€ of medical honoraria (17%), 73 M€ of hospital extra cost (15%), 99 M€ of drug provision (20%) and 232 M€ of internal cost for french affiliates (48%).
authors: Cemka-Eval, 43 boulevard du Maréchal Joffre, 92340 Bourg-la-Reine, France. francis.fagnani@cemka.fr
authors: Francis
authors: F
authors: Fagnani
mesh_terms: D035843:Biomedical Research / Q000191:economics* / Q000639:trends; D003365:Costs and Cost Analysis; D016208:Databases, Factual; D004345:Drug Industry / Q000191:economics* / Q000639:trends; D004469:Economics, Hospital / Q000639:trends*; D005602:France; D006801:Humans; D010361:Patients